Institute of Psychiatric Phenomics and Genomics, Clinical Center of the University of Munich, Nussbaumstr. 7, 80336 Munich, Germany; University Medical Center Göttingen, Department of Psychiatry and Psychotherapy, Von-Siebold-Str. 5, 37075 Göttingen, Germany.
University Medical Center Göttingen, Department of Psychiatry and Psychotherapy, Von-Siebold-Str. 5, 37075 Göttingen, Germany.
Eur Neuropsychopharmacol. 2017 Jun;27(6):599-609. doi: 10.1016/j.euroneuro.2017.02.001. Epub 2017 Mar 23.
The hopes for readily implementable precision medicine are high. For many complex disorders, such as bipolar disorder, these hopes critically hinge on tangible successes in pharmacogenetics of treatment response or susceptibility to adverse events. In this article, we review the current state of pharmacogenomics of bipolar disorder including latest results from candidate genes and genome-wide association studies. The majority of studies focus on response to lithium treatment. Although a host of genes has been studied, hardly any replicated findings have emerged so far. Very small samples sizes and heterogeneous phenotype definition may be considered the major impediments to success in this field. Drawing from current experiences and successes in studies on diagnostic psychiatric phenotypes, we suggest several approaches for our way forward.
精准医学的应用前景广阔。对于许多复杂疾病，如双相情感障碍，人们对精准医学的期望很大，主要是希望在药物遗传学上能取得治疗反应或不良事件易感性方面的切实成功。本文综述了双相情感障碍的药物基因组学研究现状，包括候选基因和全基因组关联研究的最新结果。大多数研究都集中在锂治疗反应上。尽管已经研究了许多基因，但到目前为止，几乎没有发现任何可重复的结果。样本量小且表型定义异质可能是该领域成功的主要障碍。借鉴目前在诊断精神疾病表型研究中的经验和成功案例，我们为未来的研究提出了几种方法。
